IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma.
Saved in:
| Title: | IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. |
|---|---|
| Authors: | Nayak L; Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Grommes C; Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA., Psoinos C; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Reu FJ; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Takazawa A; Clinical Development, ONO Pharmaceutical Co, Ltd, Osaka, Japan., Uttarwar M; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Xia B; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Carvajal LA; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Kim S; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Sherman ML; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA., Batchelor TT; Neurology, Brigham and Women's Hospital, Boston, MA, USA. |
| Source: | Future oncology (London, England) [Future Oncol] 2026 Jun 19, pp. 1-7. Date of Electronic Publication: 2026 Jun 19. |
| Publication Type: | Journal Article |
| Journal Info: | Publisher: Taylor & Francis Country of Publication: England NLM ID: 101256629 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1744-8301 (Electronic) Linking ISSN: 14796694 NLM ISO Abbreviation: Future Oncol Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
| FullText | Text: Availability: 0 |
|---|---|
| Header | DbId: mdl DbLabel: MEDLINE Ultimate An: 42317052 AccessLevel: 2 PubType: Academic Journal PubTypeId: academicJournal PreciseRelevancyScore: 0 |
| IllustrationInfo | |
| Items | – Name: Title Label: Title Group: Ti Data: IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. – Name: Author Label: Authors Group: Au Data: <searchLink fieldCode="AU" term="%22Nayak+L%22">Nayak L</searchLink>; Neuro-oncology, Dana-Farber Cancer Institute, Boston, MA, USA.<br /><searchLink fieldCode="AU" term="%22Grommes+C%22">Grommes C</searchLink>; Neurology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.<br /><searchLink fieldCode="AU" term="%22Psoinos+C%22">Psoinos C</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Reu+FJ%22">Reu FJ</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Takazawa+A%22">Takazawa A</searchLink>; Clinical Development, ONO Pharmaceutical Co, Ltd, Osaka, Japan.<br /><searchLink fieldCode="AU" term="%22Uttarwar+M%22">Uttarwar M</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Xia+B%22">Xia B</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Carvajal+LA%22">Carvajal LA</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Kim+S%22">Kim S</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Sherman+ML%22">Sherman ML</searchLink>; Clinical Development, Deciphera Pharmaceuticals LLC, Waltham, MA, USA.<br /><searchLink fieldCode="AU" term="%22Batchelor+TT%22">Batchelor TT</searchLink>; Neurology, Brigham and Women's Hospital, Boston, MA, USA. – Name: TitleSource Label: Source Group: Src Data: <searchLink fieldCode="JN" term="%22101256629%22">Future oncology (London, England)</searchLink> [Future Oncol] 2026 Jun 19, pp. 1-7. <i>Date of Electronic Publication: </i>2026 Jun 19. – Name: TypePub Label: Publication Type Group: TypPub Data: Journal Article – Name: TitleSource Label: Journal Info Group: Src Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22Taylor+%26+Francis%22">Taylor & Francis </searchLink><i>Country of Publication: </i>England <i>NLM ID: </i>101256629 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1744-8301 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%2214796694%22">14796694 </searchLink><i>NLM ISO Abbreviation: </i>Future Oncol <i>Subsets: </i>MEDLINE |
| PLink | https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=42317052 |
| RecordInfo | BibRecord: BibEntity: Identifiers: – Type: doi Value: 10.1080/14796694.2026.2683574 Languages: – Code: eng Text: English PhysicalDescription: Pagination: StartPage: 1 Titles: – TitleFull: IGNITE: a phase III study of tirabrutinib versus rituximab and temozolomide combination therapy in relapsed/refractory primary central nervous system lymphoma. Type: main BibRelationships: HasContributorRelationships: – PersonEntity: Name: NameFull: Nayak L – PersonEntity: Name: NameFull: Grommes C – PersonEntity: Name: NameFull: Psoinos C – PersonEntity: Name: NameFull: Reu FJ – PersonEntity: Name: NameFull: Takazawa A – PersonEntity: Name: NameFull: Uttarwar M – PersonEntity: Name: NameFull: Xia B – PersonEntity: Name: NameFull: Carvajal LA – PersonEntity: Name: NameFull: Kim S – PersonEntity: Name: NameFull: Sherman ML – PersonEntity: Name: NameFull: Batchelor TT IsPartOfRelationships: – BibEntity: Dates: – D: 19 M: 06 Text: 2026 Jun 19 Type: published Y: 2026 Identifiers: – Type: issn-electronic Value: 1744-8301 Titles: – TitleFull: Future oncology (London, England) Type: main |
| ResultId | 1 |
